StockNews.com started coverage on shares of Nabriva Therapeutics (NASDAQ:NBRV – Free Report) in a research note published on Thursday. The brokerage issued a hold rating on the biotechnology company’s stock.
Nabriva Therapeutics Price Performance
Nabriva Therapeutics has a 52 week low of $1.22 and a 52 week high of $8.45. The company has a debt-to-equity ratio of 0.12, a current ratio of 0.85 and a quick ratio of 0.52. The firm’s 50 day moving average is $0.14. The firm has a market cap of $45.46 million, a P/E ratio of -0.07 and a beta of 1.53.
Nabriva Therapeutics Company Profile
See Also
- Five stocks we like better than Nabriva Therapeutics
- What Do S&P 500 Stocks Tell Investors About the Market?
- Semiconductor Shakeout: Finding Potential Amidst Turmoil
- What is a Secondary Public Offering? What Investors Need to Know
- Hasbro’s Management Made All the Right Calls This Quarter
- What is a buyback in stocks? A comprehensive guide for investors
- Caterpillar’s Market Reset Isn’t Over: Get Ready for Lower Prices
Receive News & Ratings for Nabriva Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nabriva Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.